An orally administrable composition for treating or reducing damage to connective tissue or for treating or reducing inflammatory symptoms associated with damage to connective tissue includes a synergistic combination of: (i) avocado/soybean unsaponifiables; and (ii) lipoic acid, or a salt or derivative thereof. Methods for treating or reducing damage to connective tissue, for treating or reducing inflammatory symptoms associated with damage to connective tissue, or for reducing levels of one or more inflammatory mediators in connective tissue include administering the orally administrable composition to an avian or mammalian subject.
An anxiolytic composition formulated for oral administration to a mammal includes a synergistic combination of L-theanine, at least one of magnolia and an extract of magnolia, and at least one of phellodendron and an extract of phellodendron. The composition may include a combination of an extract of Magnolia officinalis and a extract of Phellodendron amurense. The synergistic combination may provide an anxiolytic change in a release pattern of one or more brain neurotransmitters, such as glutamate and/or γ-aminobutyric acid (GABA).
A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
A nutritional supplemental for a human or animal, such as a dog or a cat, which includes a partially hydrophobic coating applied to a tablet, is provided. The tablet includes SAMe (S-Adenosylmethionine) milk thistle, and/or any other hydroscopic raw material. SAMe is typically used as an active ingredient to support the liver of the animal. The coating of the tablet typically includes a polymer or resin, stearic acid as a moisture barrier, and calcium carbonate. The coating may also include a plasticizer and color agent. The polymer or resin is typically hydroxypropyl methyl cellulose, and the plasticizer typically includes triethyl citrate and optionally lecithin.
A61K 9/28 - DragéesPilules ou comprimés avec revêtements
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
A61K 36/28 - Asteraceae ou Compositae (famille de l'aster ou du tournesol), p. ex. camomille, chrysanthème matricaire, achillée ou echinacée
The present disclosure relates to the synergistic combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, a cofactor of the enzyme, and a glucan. The present disclosure also relates to the synergistic combination of sulforaphane or a derivative thereof and a glucan. The present disclosure also relates to the synergistic combination of a broccoli extract or powder and a glucan. The glucan may be a β-glucan. The glucan may be provided in a mushroom extract or powder selected from one or more of a maitake, a shiitake, or a reishi mushroom. Compositions and methods relating to these combinations are described.
A61K 38/47 - Hydrolases (3) agissant sur des composés glycosyliques (3.2), p. ex. cellulases, lactases
A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
A61K 9/28 - DragéesPilules ou comprimés avec revêtements
A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
A61K 31/194 - Acides carboxyliques, p. ex. acide valproïque ayant plusieurs groupes carboxyle, p. ex. acides succinique, maléique ou phtalique
A61K 31/26 - Esters d'acide cyanique ou isocyaniqueEsters d'acide thiocyanique ou isothiocyanique
A61K 31/357 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant plusieurs atomes d'oxygène dans le même cycle, p. ex. éthers en couronne, guanadrel
A61K 31/375 - Acide ascorbique, c.-à-d. vitamine CSes sels
A61K 31/7028 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques
Compositions are described including a combination of hydroxytyrosol and 3-O-acetyl-11-keto-β-boswellic acid. The hydroxytyrosol may be sourced from an olive extract and the 3-O-acetyl-11-keto-β-boswellic acid may be sourced from a Boswellia serrata extract. The compositions may be formulated for oral administration to a mammalian or an avian subject. Methods for preventing or reducing an inflammatory response in connective tissue are provided, the methods comprising orally administering the compositions to a subject in need thereof.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
On-line retail store services featuring dietary and nutritional supplements Dietary and nutritional supplements Providing information in the fields of health and wellness
A nutritional supplemental for a human or animal, such as a dog or a cat, which includes a partially hydrophobic coating applied to a tablet, is provided. The tablet includes SAMe (S-Adenosylmethionine) milk thistle, and/or any other hydroscopic raw material. SAMe is typically used as an active ingredient to support the liver of the animal. The coating of the tablet typically includes a polymer or resin, stearic acid as a moisture barrier, and calcium carbonate. The coating may also include a plasticizer and color agent. The polymer or resin is typically hydroxypropyl methyl cellulose, and the plasticizer typically includes triethyl citrate and optionally lecithin.
A61K 31/7052 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides
A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
Phellodendron amurense. The synergistic combination may provide an anxiolytic change in a release pattern of one or more brain neurotransmitters, such as glutamate and/or γ-aminobutyric acid (GABA).
A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
A soft chew nutritional supplement for an animal, such as a dog or cat, is provided. The soft chew includes (a) palm oil and/or palm oil constituent, (b) palm kernel oil and/or coconut oil, and (c) at least one other oil. The method of manufacturing the soft chew typically includes partially curing the soft chew at -79 to 0°C before packaging the soft chew, and then allowing the soft chew to fully cure while in the packaging at room temperature. To achieve the desired processing and curing of the soft chew, the ratio of the total amount of the components (a) and (b) to the total amount of the (c) other oil ranges from 45:55 to 55:45. In addition, the components (a) and (b) have a Mettler Dropping Point ranging from 36oC to 40o C and are present in an amount of 4.5 wt. % to 6.5 wt. %.
A23K 20/158 - Acides grasGraissesProduits contenant des huiles ou des graisses
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
The present disclosure application relates to cannabis-containing compositions comprising at least one cannabinoid, provided in a gel formulation. The compositions may include cannabidiol. The source of the cannabidioid may be cannabis, a cannabis extract, or an industrial hemp oil extract. Methods of treating and/or reducing symptoms of an inflammatory response and/or inflammation are described, comprising administering to a subject in need thereof the disclosed compositions.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A composition including a Moringa plant component for treating, preventing, reducing the occurrence of, decreasing the symptoms associated with, and/or reducing secondary recurrences of cancer in a subject is provided. The composition may comprise a Moringa plant component in an amount of 1 mg to 1750 mg, and sulforaphane or a sulforaphane derivative in an amount of 1 mg to 50 mg. Alternatively, the composition may comprise a Moringa plant component in an amount of 150 mg to 1500 mg sulforaphane precursor in an amount of 1 mg to 50 mg. The Moringa plant component can be Moringa leaf extract containing 10 mg of moringin per 1000 mg of the Moringa leaf extract. The composition may also include at least one of a mushroom extract or powder and a broccoli extract or powder.
MoringaMoringaMoringaMoringaMoringaMoringaMoringa leaf extract. The composition may also include at least one of a mushroom extract or powder and a broccoli extract or powder.
The present application relates to compositions comprising avocado/soybean unsaponifiables (“ASU”) and cannabis, and related methods of use. In one embodiment, the cannabis is a cannabis oil extract that is combined with ASU to reduce inflammatory responses and inflammation in humans and animals.
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61K 36/48 - Fabaceae ou Leguminosae (famille du pois ou des légumineuses)CaesalpiniaceaeMimosaceaePapilionaceae
A61K 36/54 - Lauraceae (famille du laurier), p. ex. cannelle ou sassafras
05 - Produits pharmaceutiques, vétérinaires et hygièniques
35 - Publicité; Affaires commerciales
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
(1) Allergy medication; allergy tablets; amino acid dietary supplements; anti-oxidants for use as dietary supplements; digestive enzymes used to treat food allergies in pets; minerals; nutraceuticals for use as a dietary supplement for general health and well-being; nutritional supplements for animal foodstuffs; prebiotic supplements; probiotic supplements; protein supplements for animals; vitamins; dietary and nutritional supplements for human joint health and flexibility, for healthy immune system for humans; veterinary pharmaceuticals for the treatment of arthritis, degenerative joints, degenerative bones, nutrient deficiencies, vitamin deficiencies, mineral deficiencies, kidney disease, liver disease, heart disease, fertility conditions, reproductive diseases, respiratory infections, diabetes, endocrine gland infections, brain tumors, brain disease, central nervous system diseases, peripheral nervous system disorders, skeletal degeneration, muscle degeneration and soreness, auto-immune disorders, immune system regulation, and infections of animal digestive tracts, urinary tracts, skins and coats; dietary, nutritional and herbal supplements for animal use for joint and bone health, for liver health, for digestive health, for skin and coat health, for brain health, for function, for urinary health, for heart health, to support renal function, to support nervous system function, for immune system function and for dental health; dietary, nutritional and herbal supplements to treat skin allergies in animals; all of the foregoing sold via pharmacies, department stores, online retail stores, drugstores, pet stores and veterinary clinics (1) Wholesale and online sale of pharmaceutical preparations and dietary, nutritional and herbal supplements for animal and human use via a website
(2) Providing information on dietary, nutritional and herbal supplements for animal and human use via a website
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Dietary and nutritional supplements for general health and wellbeing; dietary and nutritional supplements for pets for maintaining a healthy digestive system; dietary supplement for eliminating toxins from the intestinal tract; dietary supplements for general health and well-being; digestive enzymes used to treat exocrine pancreatic insufficiency (EPI) for veterinary purposes; herbal supplements for general health and well-being; mineral supplements; minerals; nutritional supplements for animal foodstuffs; nutritional supplements for general health and well-being; nutritional supplements for maintaining a healthy digestive system; vitamin supplements; vitamins
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Shampoos; skin care preparations; skin creams
(2) Allergy medication; allergy medications; anti-inflammatories; antifungal creams for medical purposes; antihistamines; antimicrobials for dermatologic use; antiseptics; decongestants; dietary and nutritional supplements for general health and wellbeing; dietary and nutritional supplements for pets for maintaining a healthy digestive system; dietary supplements for general health and well-being; herbal supplements for general health and well-being; mineral supplements; minerals; nutritional supplements for animal foodstuffs; nutritional supplements for general health and well-being; pharmaceutical preparations for treating allergies; topical anti-inflammatories; vitamin supplements; vitamins
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Dietary and nutritional supplements for general health and wellbeing; dietary and nutritional supplements for pets for maintaining a healthy digestive system; dietary supplement for eliminating toxins from the intestinal tract; dietary supplements for general health and well-being; herbal supplements for general health and well-being; mineral supplements; minerals; nutritional supplements for animal foodstuffs; nutritional supplements for general health and well-being; nutritional supplements for maintaining a healthy digestive system; probiotic supplements; vitamin supplements; vitamins
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Dietary and nutritional supplements for general health and wellbeing; dietary and nutritional supplements for pets for maintaining a healthy digestive system; dietary supplement for eliminating toxins from the intestinal tract; dietary supplements for general health and well-being; herbal supplements for general health and well-being; mineral supplements; minerals; nutritional supplements for animal foodstuffs; nutritional supplements for general health and well-being; nutritional supplements for maintaining a healthy digestive system; vitamin supplements; vitamins
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Antioxidant supplements for pets; dietary and nutritional supplements for general health and wellbeing; dietary and nutritional supplements for pets for maintaining a healthy digestive system; dietary supplement for eliminating toxins from the intestinal tract; dietary supplements for general health and well-being; herbal supplements for general health and well-being; mineral supplements; minerals; nutritional supplements for animal foodstuffs; nutritional supplements for general health and well-being; nutritional supplements for maintaining a healthy digestive system; vitamin supplements; vitamins
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Botanical supplements for general health and well-being; dietary and nutritional supplements for general health and wellbeing; dietary supplements consisting of amino acids; dietary supplements consisting of trace elements; dietary supplements for general health and well-being; herbal supplements for general health and well-being; minerals; nutritional supplements for general health and well-being; vitamin and mineral supplements; vitamins
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Dietary and nutritional supplements to support joint health in animals; dietary pet supplements in the form of pet treats to support joint health in animals
The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and a milk thistle extract or powder. The invention also relates to the combination of a sulforaphane or a derivative thereof and a milk thistle extract or powder. The invention also relates to the combination of a broccoli extract or powder and a milk thistle extract or powder. The invention provides compositions and methods relating to these combinations.
A61K 31/357 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant plusieurs atomes d'oxygène dans le même cycle, p. ex. éthers en couronne, guanadrel
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
Boswellia serrata extract. The compositions may be formulated for oral administration to a mammalian or an avian subject. Methods for treating, repairing, or reducing damage to connective tissue caused by one or more inflammatory mediators and for reducing levels of one or more inflammatory mediators in connective tissue are provided, the methods comprising orally administering the compositions to a subject in need thereof.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Edible preparations, namely, a pliable paste and dough like substance for the delivery of medicine and nutritional supplements to animals sold without medicine
The present disclosure application relates to cannabis-containing compositions comprising at least one cannabinoid, provided in a gel formulation. The compositions may include cannabidiol. The source of the cannabidioid may be cannabis, a cannabis extract, or an industrial hemp oil extract. Methods of treating and/or reducing symptoms of an inflammatory response and/or inflammation are described, comprising administering to a subject in need thereof the disclosed compositions.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61K 36/28 - Asteraceae ou Compositae (famille de l'aster ou du tournesol), p. ex. camomille, chrysanthème matricaire, achillée ou echinacée
85.
Compositions comprising sulforaphane or a sulforaphane precursor and a mushroom extract or powder
The present disclosure relates to the synergistic combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, a cofactor of the enzyme, and a glucan. The present disclosure also relates to the synergistic combination of sulforaphane or a derivative thereof and a glucan. The present disclosure also relates to the synergistic combination of a broccoli extract or powder and a glucan. The glucan may be a β-glucan. The glucan may be provided in a mushroom extract or powder selected from one or more of a maitake, a shiitake, or a reishi mushroom. Compositions and methods relating to these combinations are described.
A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
A61K 9/28 - DragéesPilules ou comprimés avec revêtements
A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
A61K 31/194 - Acides carboxyliques, p. ex. acide valproïque ayant plusieurs groupes carboxyle, p. ex. acides succinique, maléique ou phtalique
A61K 31/26 - Esters d'acide cyanique ou isocyaniqueEsters d'acide thiocyanique ou isothiocyanique
A61K 31/357 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant plusieurs atomes d'oxygène dans le même cycle, p. ex. éthers en couronne, guanadrel
A61K 31/375 - Acide ascorbique, c.-à-d. vitamine CSes sels
A61K 31/7028 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques
A61K 33/06 - Aluminium, calcium ou magnésiumLeurs composés
A61K 36/00 - Préparations médicinales de constitution indéterminée contenant du matériel provenant d'algues, de lichens, de champignons, ou de plantes, ou leurs dérivés, p. ex. médicaments traditionnels à base de plantes
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61K 36/48 - Fabaceae ou Leguminosae (famille du pois ou des légumineuses)CaesalpiniaceaeMimosaceaePapilionaceae
A61K 36/54 - Lauraceae (famille du laurier), p. ex. cannelle ou sassafras
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
88.
COMPOSITIONS COMPRISING SULFORAPHANE OR A SULFORAPHANE PRECURSOR AND MAGNESIUM
The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and magnesium or a salt or complex thereof. The invention also relates to the combination of a sulforaphane or a derivative thereof and magnesium or a salt or complex thereof. The invention also relates to the combination of a broccoli extract or powder and magnesium or a salt or complex thereof. The invention provides compositions and methods relating to these combinations.
A61K 31/357 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant plusieurs atomes d'oxygène dans le même cycle, p. ex. éthers en couronne, guanadrel
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
Produits et services
Nutritional proprietary ingredient blend comprised of mushroom extract and yeast extract for use as an ingredient in the manufacture of dietary supplements
90.
Compositions comprising sulforaphane or a sulforaphane precursor and a milk thistle extract or powder
The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and a milk thistle extract or powder. The invention also relates to the combination of a sulforaphane or a derivative thereof and a milk thistle extract or powder. The invention also relates to the combination of a broccoli extract or powder and a milk thistle extract or powder. The invention provides compositions and methods relating to these combinations.
A61K 31/357 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant plusieurs atomes d'oxygène dans le même cycle, p. ex. éthers en couronne, guanadrel
Boswellia serrata extract. The compositions may be formulated for oral administration to a mammalian or an avian subject. Methods for preventing or reducing an inflammatory response in connective tissue are provided, the methods comprising orally administering the compositions to a subject in need thereof.
The present disclosure relates to the synergistic combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, a cofactor of the enzyme, and a glucan. The present disclosure also relates to the synergistic combination of sulforaphane or a derivative thereof and a glucan. The present disclosure also relates to the synergistic combination of a broccoli extract or powder and a glucan. The glucan may be a β-glucan. The glucan may be provided in a mushroom extract or powder selected from one or more of a maitake, a shiitake, or a reishi mushroom. Compositions and methods relating to these combinations are described.
A61K 31/357 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant plusieurs atomes d'oxygène dans le même cycle, p. ex. éthers en couronne, guanadrel
96.
Orally administrable compositions comprising avocado/soybean unsaponifiables and lipoic acid and methods of administration
An orally administrable composition for treating or reducing damage to connective tissue or for treating or reducing inflammatory symptoms associated with damage to connective tissue includes a synergistic combination of: (i) avocado/soybean unsaponifiables; and (ii) lipoic acid, or a salt or derivative thereof. Methods for treating or reducing damage to connective tissue, for treating or reducing inflammatory symptoms associated with damage to connective tissue, or for reducing levels of one or more inflammatory mediators in connective tissue include administering the orally administrable composition to an avian or mammalian subject.
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
Boswellia serrata extract. The compositions may be formulated for oral administration to a mammalian or an avian subject. Methods for treating, repairing, or reducing damage to connective tissue caused by one or more inflammatory mediators and for reducing levels of one or more inflammatory mediators in connective tissue are provided, the methods comprising orally administering the compositions to a subject in need thereof.
